PATH vs SLDB · P/E 19, rev $1.61B vs rev $8.1M
Uipath Inc (PATH) versus Solid Biosciences LLC (SLDB) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Solid Biosciences LLC (SLDB) is a biotechnology company listed on US.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported SLDB revenue for 2022-12-31 was $8.1M. Net income was -$86.0M. SLDB currently screens at market cap $389.9M.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. SLDB currently screens at market cap $389.9M.
Not investment advice. Open the PATH and SLDB stock pages for the full models.
Not investment advice.